

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of  
FUKUDA et al.

Group/Art Unit: Not Available

Parent: PCT/JP01/03308

Examiner: Not Available

U.S. Application No: 10/018,245

U.S. Filing Date: December 18, 2001

For: NOVEL RECOMBINANT ANTIBODY, AMINO ACID SEQUENCES  
OF ITS COMPLEMENTARITY DETERMINING REGIONS AND  
GENES ENCODING THE SAME

\* \* \* \* \*

July 12, 2002

RESPONSE AND SUBMISSION  
PURSUANT TO 37 CFR 1.821-1.825

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

Sir:

In response to the Notification of Defective Response mailed on June 12, 2002 (copy attached hereto), and in compliance with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (under 37 CFR 1.821 - 1.825), please enter the attached substitute sequence listing and amend the above-referenced application as follows.

**IN THE SPECIFICATION:**

Please cancel the 9 pages of sequence listing (pages 1/9-6/9) originally filed with this U.S. application.

Please add the attached pages 25-29 to the Specification. Please renumber original pages 25-27 of the Specification accordingly.

**REMARKS**

A Notification of Defective Response was mailed on June 12, 2002 (copy attached hereto). The Notification states that the applicants must provide an initial or substitute sequence listing and an amendment directing its entry into the specification.

In accordance with 37 CFR 1.821(c), a "Sequence Listing" is submitted herewith, and in accordance with the present Amendment, it is respectfully requested that the Listing be entered into the application. The Sequence Listing does not include new matter. A copy of the "Sequence Listing" in computer readable form is also submitted herewith, in accordance with 37 CFR 1.821(e), and includes no new matter.

Furthermore, in accordance with 37 CFR 1.821(f), it is submitted that the contents of the paper copy and the computer readable copy of the Sequence Listing are the same.

In view of the above, it is respectfully submitted that the above-identified application complies with the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

Respectfully Submitted,

Manelli Denison & Selter, PLLC

By Paul E. White, Jr.

Paul E. White, Jr.  
Reg. No. 32,011  
Tel. No.: (202) 261-1050  
Fax No.: (202) 887-0336

2000 M Street, N.W.  
Seventh Floor  
Washington, D.C. 20036-3307  
(202) 261-1000



## UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
 United States Patent and Trademark Office  
 Washington, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/018,245	Yoshiaki Fukuda	46/224

Paul White  
 Manelli Denison & Selter  
 2000 M Street NW  
 7th Floor  
 Washington, DC 20036

## INTERNATIONAL APPLICATION NO.

PCT/JP01/03308

## I.A. FILING DATE

## PRIORITY DATE

04/18/2001

**CONFIRMATION NO. 8337**  
**371 FORMALITIES LETTER**



\*OC00000008255774\*

Date Mailed: 06/12/2002

**NOTIFICATION OF DEFECTIVE RESPONSE**

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).**

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
  - **APPLICANT MUST PROVIDE:**

- An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice MUST be returned with the response.*

LAMONT M HUNTER

---

Telephone: (703) 305-3686

PART 2 - OFFICE COPY

---

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/018,245	PCT/JP01/03308	46/224

FORM PCT/DO/EO/916 (371 Formalities Notice)